|
Patent landscape, scope, and claims: |
US Patent 12,599,611 Landscape: Scope, Claim Coverage, and Competitive Risk for Intranasal Diazepam in Pediatric Seizure Clusters
US Patent 12,599,611 is directed to intranasal diazepam for intermittent, stereotypic episodes of frequent seizure activity in pediatric epilepsy patients, with highly specific drug product composition and dosing mechanics (single spray volumes, nostril targeting, excipient package) and a performance/clinical-treatment window (seizure control duration, timing relative to seizure phases, and bioavailability). The claims are structured as a matrix of (i) age and weight bands, (ii) diazepam strength (50 mg/mL, 75 mg/mL, 100 mg/mL), (iii) one-spray dosing format, and (iv) carrier formulation including benzyl alcohol, dodecyl maltoside, and optionally vitamin E plus ethanol.
What does US Patent 12,599,611 claim for intranasal diazepam?
Core claimed invention (all independent claim families you provided).
The claims you listed cover a method of treating seizure clusters described as “intermittent, stereotypic episodes of frequent seizure activity that are distinct from a subject’s usual seizure pattern” in pediatric epilepsy patients by intranasal administration to nasal mucosal membrane using a defined intranasal pharmaceutical solution.
Claim structure that matters for scope
-
Patient phenotype and population
- Pediatric epilepsy with “intermittent, stereotypic episodes” and a distinct usual seizure pattern.
- Patient age range: 2 to 5 years old.
- Patient weight bands used to set which diazepam strength is claimed:
- 23 to 33 kg (Claim 1; diazepam 75 mg/mL)
- 6 to 11 kg (Claim 12; diazepam 50 mg/mL)
- 12 to 22 kg (Claim 23; diazepam 100 mg/mL)
-
Intranasal dosing geometry
- A fixed dose volume: 100 µL total.
- Nose targeting differs by claim set:
- Claim 1 (75 mg/mL): one spray in each nostril (split across both nostrils) totaling 100 µL pharmaceutical solution.
- Claim 12 and 23: one spray in a single nostril totaling 100 µL.
-
Drug substance concentration
- Diazepam concentration is tightly tied to the weight/age band:
- 75 mg/mL (Claim 1)
- 50 mg/mL (Claim 12)
- 100 mg/mL (Claim 23)
-
Excipients and carrier system (key for design-around)
- Required in all listed independent claims:
- 0.25% w/v dodecyl maltoside
- 10.5% w/v benzyl alcohol
- Optional dependent add-ons:
- 56.5% w/v vitamin E (Claims 2, 13, 24)
- ethanol amount sufficient to reach volume 100 µL (Claims 2, 13, 24)
-
Delivery device and self-administration
- Dependent claims specify:
- Pre-primed single use dosage device (Claims 3, 14, 25)
- Self-administered by the subject (Claims 11, 22, 33)
Clinical-performance limitations that narrow enforceable scope
Dependent claims add treatment effect and timing requirements:
-
At least 48 hours reduction of clinical seizure activity (Claims 4, 15, 26)
-
Prevents a second seizure for at least 8 hours (Claims 5, 16, 27)
-
Prevents a second seizure for at least 48 hours (Claims 6, 17, 28)
-
No second administration within at least 24 hours after a first seizure (Claims 7, 18, 29)
-
Administration phase relative to seizure:
- Prodromal or pre-ictal phase (Claims 8, 19, 30)
- Ictal phase (Claims 9, 20, 31)
-
Bioavailability:
- Achieves 96% to 97% bioavailability of an equivalent IV diazepam dose (Claims 10, 21, 32)
These features matter in enforcement because they create “method of treatment” hooks that are harder for a generic/alternative product to avoid if the new product’s administration protocol and observed performance match the claimed regimen.
How broad is claim scope: drug product + method + patient weight/age bands?
Broadness in one dimension, narrowness in another.
The claims are broad as to purpose (treating seizure clusters) but narrow as to formulation, dose mechanics, and the pediatric demographic qualifiers.
Key scope boundaries
-
Composition is constrained
- Any design-around that changes:
- dodecyl maltoside concentration,
- benzyl alcohol concentration,
- diazepam concentration, or
- the overall formulation “carrier system” concept,
will attempt to fall outside literal coverage.
-
Dosing mechanics constrain infringement
- “One spray in each nostril” vs “one spray in a single nostril” is a meaningful mechanical limitation.
- Intranasal dose volume is fixed at 100 µL in your independent-claim language.
-
Weight/age band mapping is a claim boundary
- The diazepam strength is paired to patient weight bands.
- That pairing supports an argument that the claims are intended to cover a specific pediatric dosing algorithm.
-
Bioavailability and seizure-duration endpoints create evidentiary burdens
- “96% to 97% bioavailability” is quantitative.
- Method-of-treatment performance claims often become claim-construction and proof battlegrounds.
Practical infringement scenarios based on the claim matrix
| Scenario |
Likely risk vs 12,599,611 |
| Using intranasal diazepam with the same concentrations/excipients but different spray volume |
Moderate-to-high risk depending on claim construction of “100 µL” and device delivery |
| Same diazepam formulation but different nostril strategy (single vs both) |
High risk if the targeted patient/weight band maps to the independent claim language |
| Same dosing mechanics but different excipient package (e.g., no benzyl alcohol or different solubilizer) |
Lower risk if excipient constraints are essential and not met |
| Different diazepam strength for same pediatric weight band |
High risk for those users if they still meet an independent claim element by element |
| Same composition but different administration timing (e.g., only post-ictal) |
Lower risk for dependent claims that require prodromal/ictal timing |
| Product performs differently on bioavailability (not 96-97% of IV) |
Risk drops for those dependent claim pathways; independent claims may still be asserted depending on claim set |
Which dependent claims add strongest enforceable hooks?
From the dependent claims you provided, the most litigation-relevant are the ones that add objective, testable, or operational restrictions.
Strong “objective” limitations (best for claim proof)
- Bioavailability 96% to 97% (Claims 10, 21, 32)
- At least 48 hours seizure activity reduction (Claims 4, 15, 26)
- Second seizure prevention durations 8 hours and 48 hours (Claims 5-6, 16-17, 27-28)
- No second administration within at least 24 hours (Claims 7, 18, 29)
Strong “operational” limitations (best for prescribing/use arguments)
- Prodromal/pre-ictal vs ictal phase administration (Claims 8-9, 19-20, 30-31)
- Pre-primed single use dosage device (Claims 3, 14, 25)
- Self-administered by the subject (Claims 11, 22, 33)
What patent landscape risks exist around these claims (formulation, device, and method-of-use)?
A full landscape requires the patent’s complete bibliographic record and the broader family map. Your prompt provides only the claim text, not the application history, examiner outcomes, family members, or cited references. Under those constraints, the actionable landscape below focuses on what this patent is likely to overlap with, based on the claimed feature set.
Likely overlapping claim themes in adjacent patents
-
Intranasal diazepam composition patents
- Diazepam in a surfactant-rich intranasal carrier with benzyl alcohol and solubilizer systems
- Vitamin E as an excipient add-on to stabilize or permeabilize
-
Intranasal dosing algorithms in pediatric epilepsy
- Weight-band-specific concentration and spray regimen
- Single nostril vs split nostril depending on volume/dose targeting
-
Device and usability claims
- Pre-primed, single-use delivery systems
- Self-administration or caregiver administration mechanics
-
Method-of-use patents for seizure clusters
- “Intermittent stereotypic episodes” distinct from baseline seizure patterns
- Use in prodromal/pre-ictal vs ictal phases
- Timing endpoints like “prevents a second seizure” durations and “no second administration within 24 hours”
Where this patent is easiest to design around
- Substitute excipients to remove one or more required constraints:
- dodecyl maltoside at 0.25% w/v
- benzyl alcohol at 10.5% w/v
- remove vitamin E (if it is required via dependent claim strategy)
- Change delivery mechanics:
- nostril targeting
- spray volume not equal to 100 µL
- Use different diazepam concentrations that do not match the weight-band mapping
Where design-around is hardest
- If a competing product uses essentially the same formulation and dosing algorithm and produces similar seizure control outcomes, it is difficult to avoid both:
- literal satisfaction of elements, and
- infringement by doctrine-of-equivalents arguments for “substantially” identical performance (especially for the quantitative bioavailability and seizure-duration endpoints).
When does US Patent 12,599,611 lose exclusivity (patent term timing)?
No term-loss calculation can be produced from claim language alone. A reliable timeline requires the patent’s filing date, priority dates, any PTA, and whether it is subject to terminal disclaimer. Without those bibliographic data, any exclusivity or expiration estimate would be ungrounded.
What generic entry risks exist for intranasal diazepam under this patent?
Even without Orange Book or regulatory dossier data, the claim content implies high leverage points against generic entry:
Risk drivers for a generic or follow-on intranasal diazepam
- If the generic uses the same excipient package and dosing mechanics, it is likely to overlap substantially with the claims.
- If the generic tries to claim different bioavailability or different clinical endpoints, those outcomes can be attacked using comparative clinical pharmacology and seizure control studies.
- If the generic product includes the same pre-primed single-use device concept, it increases the risk that multiple dependent claims are asserted.
What a “low-risk” generic design would likely do (conceptually)
- Use a different surfactant system than dodecyl maltoside at 0.25% w/v.
- Remove or replace benzyl alcohol at 10.5% w/v.
- Recalibrate intranasal volumes and spray geometry away from “100 µL” and “one spray” arrangements used here.
- Ensure it does not match the claimed weight-band diazepam strengths and device/dosing instructions that map onto dependent claim limitations.
How strong is the patent estate for these claims?
Based only on the claim set you provided, strength can be assessed at the claim-design level but not as a complete estate metric (number of family members, claim survival rates, maintenance status, or litigation history). Strength indicators present in the claims:
- Multiple independent claim families appear represented by different patient weight bands and diazepam strengths (75 mg/mL, 50 mg/mL, 100 mg/mL).
- The claims include multiple dependent clauses that add operational and measurable performance constraints.
- The formulation is detailed enough to create meaningful barriers to close substitutes.
Weakness indicators (also claim-design level):
- Over-specific quantitative and dosing-limit constraints can also reduce enforcement breadth if an accused product deviates.
- The method-of-use endpoints require evidence; if real-world outcomes differ, some dependent claims may be harder to prove.
Key Takeaways
- US Patent 12,599,611 claims intranasal diazepam methods for pediatric epilepsy seizure clusters, defined by “intermittent, stereotypic episodes” distinct from baseline seizure patterns.
- Claim scope is a matrix of: pediatric age, patient weight band, diazepam concentration (50, 75, 100 mg/mL), intranasal spray geometry (single vs both nostrils), and a constrained carrier formulation (including 0.25% w/v dodecyl maltoside and 10.5% w/v benzyl alcohol, with optional 56.5% w/v vitamin E and ethanol to reach 100 µL).
- Dependent claims add strong, testable hooks: bioavailability (96% to 97%) and seizure-control duration endpoints (e.g., 8 hours, 48 hours, and no second administration within 24 hours), plus device and administration-phase limits.
- For competitors, the most actionable design-around levers implied by the claims are formulation excipient changes, diazepam concentration changes, and intranasal delivery geometry/volume changes, followed by divergence from the claimed seizure timing and performance endpoints.
FAQs
1) Does US 12,599,611 cover caregiver administration or only self-administration?
Your provided claims include a dependent limitation that the pharmaceutical solution is self-administered by the subject (Claims 11, 22, 33). The claim text you supplied does not state caregiver administration; the landscape coverage would depend on the rest of the claim set not included here.
2) Are prodromal/pre-ictal administrations separately protected from ictal-phase dosing?
Yes. Dependent claims separately recite administration in prodromal/pre-ictal phase (Claims 8, 19, 30) and in the ictal phase (Claims 9, 20, 31).
3) What formulation elements are mandatory versus optional in the claims you listed?
Mandatory across the listed independent claims include diazepam concentration (set by claim family), 0.25% w/v dodecyl maltoside, and 10.5% w/v benzyl alcohol. Vitamin E (56.5% w/v) and ethanol sufficient to reach 100 µL appear in dependent claims (Claims 2, 13, 24).
4) Can a product avoid infringement by changing bioavailability away from 96%-97%?
For the dependent claims tied to 96% to 97% bioavailability (Claims 10, 21, 32), shifting outside that range could reduce infringement likelihood for those dependent claims. Independent claims and other dependent claims would still need element-by-element comparison.
5) Does the patent require different nostril targeting by weight band?
Yes. In your independent claims: one regimen uses one spray in each nostril (Claim 1, 75 mg/mL cohort), while other regimens use one spray in a single nostril (Claims 12 and 23 cohorts).
References
- US Patent 12,599,611 (claims text provided in prompt).
More… ↓
⤷ Start Trial
|
